Cochrane · systematic review · CD012997
Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome
Imdad, A, Mackoff, SP, Urciuoli, DM, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
27
current version
GRADE rated
14
No studies
13
Included studies
NR
No studies 13 · 48.1%Ungraded 0 · 0%Very low 10 · 37%Low 4 · 14.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antibiotics versus no treatment for secondary prevention of HUS
Population: patients with diarrhoea due to Shiga toxin‐producing E. coli
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of HUS Antibiotics vs no treatment | RR 0.57 [0.11, 2.81] | 1 study · 47 participants | Very low Downgraded: risk of bias |
Adverse events Antibiotics vs no treatment | no estimate extracted | NR | No studies |
Need for acute dialysis Antibiotics vs no treatment | no estimate extracted | NR | No studies |
Neurological complications Antibiotics vs no treatment | no estimate extracted | NR | No studies |
Death (any cause) Antibiotics vs no treatment | no estimate extracted | NR | No studies |
Bovine colostrum versus placebo for secondary prevention of HUS
Population: patients with diarrhoea due to Shiga toxin‐producing E. coli
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of HUS Bovine colostrum vs placebo | no estimate extracted | 1 study · 27 participants | Very low Downgraded: risk of bias |
Adverse events Bovine colostrum vs placebo | RR 0.92 [0.42, 2.03] | 1 study · 27 participants | Very low Downgraded: risk of bias |
Need for acute dialysis Bovine colostrum vs placebo | no estimate extracted | NR | No studies |
Neurological complications Bovine colostrum vs placebo | no estimate extracted | NR | No studies |
Death (any cause) Bovine colostrum vs placebo | no estimate extracted | NR | No studies |
Synsorb Pk versus placebo for secondary prevention of HUS
Population: patients with diarrhoea due to Shiga toxin‐producing E. coli
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of HUS Synsorb Pk vs placebo | RR 0.93 [0.39, 2.22] | 1 study · 353 participants | Very low Downgraded: risk of bias |
Adverse events Synsorb Pk vs placebo | no estimate extracted | NR | No studies |
Need for acute dialysis Synsorb Pk vs placebo | no estimate extracted | NR | No studies |
Neurological complications Synsorb Pk vs placebo | no estimate extracted | NR | No studies |
Death (any cause) Synsorb Pk vs placebo | no estimate extracted | NR | No studies |
Urtoxazumab (3.0 mg/kg) versus placebo for secondary prevention of HUS
Population: paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of HUS Urtoxazumab (3.0 mg/kg) vs placebo | RR 0.34 [0.01, 8.14] | 1 study · 71 participants | Very low Downgraded: risk of bias |
Adverse events ‐ treatment emergent Urtoxazumab (3.0 mg/kg) vs placebo | RR 1 [0.84, 1.18] | 1 study · 71 participants | Low Downgraded: risk of bias |
Adverse events ‐ serious Urtoxazumab (3.0 mg/kg) vs placebo | no estimate extracted | 1 study · 71 participants | Low Downgraded: risk of bias |
Need for acute dialysis Urtoxazumab (3.0 mg/kg) vs placebo | no estimate extracted | NR | No studies |
Neurological complications Urtoxazumab (3.0 mg/kg) vs placebo | RR 2.06 [0.2, 21.68] | 1 study · 71 participants | Very low Downgraded: risk of bias |
Death (any cause) Urtoxazumab (3.0 mg/kg) vs placebo | RR 0.34 [0.01, 8.14] | 1 study · 71 participants | Very low Downgraded: risk of bias |
Urtoxazumab (1.0 mg/kg) versus placebo for secondary prevention of HUS
Population: paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of HUS Urtoxazumab (1.0 mg/kg) vs placebo | RR 0.95 [0.06, 14.59] | 1 study · 74 participants | Very low Downgraded: risk of bias |
Adverse events ‐ treatment emergent Urtoxazumab (1.0 mg/kg) vs placebo | RR 0.95 [0.79, 1.13] | 1 study · 74 participants | Low Downgraded: risk of bias |
Adverse events ‐ serious Urtoxazumab (1.0 mg/kg) vs placebo | no estimate extracted | 1 study · 74 participants | Low Downgraded: risk of bias |
Need for acute dialysis Urtoxazumab (1.0 mg/kg) vs placebo | no estimate extracted | NR | No studies |
Neurological complications Urtoxazumab (1.0 mg/kg) vs placebo | RR 2.84 [0.31, 26.08] | 1 study · 74 participants | Very low Downgraded: risk of bias |
Death (any cause) Urtoxazumab (1.0 mg/kg) vs placebo | RR 0.95 [0.06, 14.59] | 1 study · 74 participants | Very low Downgraded: risk of bias |